On September 8, 2025 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered by AI/ML reported it will present research at the Single Cell Genomics 2025 Conference taking place September 15-17, 2025, in Stockholm, Sweden (Press release, Compugen, SEP 8, 2025, View Source [SID1234655842]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This research reflects Compugen’s computational capabilities in understanding the spatial context of complex cancer biology that may inform drug discovery efforts and therapeutic strategies to potentially provide benefit to cancer patients.
Poster and short talk details:
Title: Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer
Presenting author: Roy Granit, Ph.D., Senior Director, Head of Computational Discovery, Compugen
Poster ID: P035
Date of presentation: September 15, 2025, at 2:10 PM CET
Poster will be available in the publications section of Compugen’s website, www.cgen.com, following presentation.